ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$71.47+1.48 (+2.11%)
Close on Nov 18, 2026Market cap $1.64BP/E 15.2Yield –
ANI Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
ANI Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $978.38M, up 30.9% year over year. For fiscal 2025 it was $883.37M, up 43.8% from the year before. Over ten years it grew 27.7% a year on average. The highest annual figure on record is $883.37M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $883.37M | +43.8% |
| FY2024 | Dec 31, 2024 | $614.38M | +26.2% |
| FY2023 | Dec 31, 2023 | $486.82M | +53.9% |
| FY2022 | Dec 31, 2022 | $316.39M | +46.4% |
| FY2021 | Dec 31, 2021 | $216.14M | +3.7% |
| FY2020 | Dec 31, 2020 | $208.48M | +0.9% |
| FY2019 | Dec 31, 2019 | $206.55M | +2.5% |
| FY2018 | Dec 31, 2018 | $201.58M | +14.0% |
| FY2017 | Dec 31, 2017 | $176.84M | +37.5% |
| FY2016 | Dec 31, 2016 | $128.62M | +68.5% |
| FY2015 | Dec 31, 2015 | $76.32M | +36.4% |
| FY2014 | Dec 31, 2014 | $55.97M | +86.1% |
| FY2013 | Dec 31, 2013 | $30.08M | +47.7% |
| FY2012 | Dec 31, 2012 | $20.37M | +4581.3% |
| FY2011 | Dec 31, 2011 | $435.16K | -82.4% |
| FY2010 | Dec 31, 2010 | $2.47M | +96.7% |
| FY2009 | Dec 31, 2009 | $1.26M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $266.04M | +25.9% |
| Q1 FY2026 | Mar 31, 2026 | $237.46M | +20.5% |
| Q4 FY2025 | Dec 31, 2025 | $247.06M | +29.6% |
| Q3 FY2025 | Sep 30, 2025 | $227.81M | +53.6% |
| Q2 FY2025 | Jun 30, 2025 | $211.37M | +53.1% |
| Q1 FY2025 | Mar 31, 2025 | $197.12M | +43.4% |
| Q4 FY2024 | Dec 31, 2024 | $190.57M | +44.8% |
| Q3 FY2024 | Sep 30, 2024 | $148.33M | +12.5% |
| Q2 FY2024 | Jun 30, 2024 | $138.04M | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | $137.43M | +28.7% |
| Q4 FY2023 | Dec 31, 2023 | $131.65M | +39.7% |
| Q3 FY2023 | Sep 30, 2023 | $131.83M | +57.3% |
| Q2 FY2023 | Jun 30, 2023 | $116.55M | +57.8% |
| Q1 FY2023 | Mar 31, 2023 | $106.79M | +65.6% |
| Q4 FY2022 | Dec 31, 2022 | $94.23M | +54.7% |
| Q3 FY2022 | Sep 30, 2022 | $83.82M | +61.0% |
| Q2 FY2022 | Jun 30, 2022 | $73.86M | +51.9% |
| Q1 FY2022 | Mar 31, 2022 | $64.48M | +18.3% |
| Q4 FY2021 | Dec 31, 2021 | $60.93M | +6.4% |
| Q3 FY2021 | Sep 30, 2021 | $52.06M | -1.7% |
| Q2 FY2021 | Jun 30, 2021 | $48.63M | +0.3% |
| Q1 FY2021 | Mar 31, 2021 | $54.52M | +9.5% |
| Q4 FY2020 | Dec 31, 2020 | $57.25M | +19.4% |
| Q3 FY2020 | Sep 30, 2020 | $52.98M | +3.2% |
| Q2 FY2020 | Jun 30, 2020 | $48.47M | -10.8% |
| Q1 FY2020 | Mar 31, 2020 | $49.77M | -5.9% |
| Q4 FY2019 | Dec 31, 2019 | $47.97M | -16.0% |
| Q3 FY2019 | Sep 30, 2019 | $51.34M | +1.3% |
| Q2 FY2019 | Jun 30, 2019 | $54.36M | +15.0% |
| Q1 FY2019 | Mar 31, 2019 | $52.89M | +13.8% |
| Q4 FY2018 | Dec 31, 2018 | $57.12M | +20.8% |
| Q3 FY2018 | Sep 30, 2018 | $50.70M | +5.3% |
| Q2 FY2018 | Jun 30, 2018 | $47.27M | +5.6% |
| Q1 FY2018 | Mar 31, 2018 | $46.48M | +26.9% |
| Q4 FY2017 | Dec 31, 2017 | $47.29M | +23.8% |
| Q3 FY2017 | Sep 30, 2017 | $48.16M | +25.0% |
| Q2 FY2017 | Jun 30, 2017 | $44.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $38.53M | – |
See a number that looks wrong?